InMode Announces Conclusion of Independent Transaction Committee Review
Rhea-AI Summary
InMode (Nasdaq: INMD) announced that its Board's independent transaction committee has completed a review of proposals for a potential transaction and determined that none of the final proposals was adequate or in shareholders' best interests.
The Committee has discontinued the process; the company will continue to evaluate business and cash allocation strategies to enhance long-term shareholder value and does not intend further updates unless appropriate or required.
Positive
- Independent committee completed a comprehensive review
- Company will refine business and cash allocation strategy
- Board prioritized shareholder interests in decision
Negative
- Potential transaction process discontinued on Feb 23, 2026
- No final proposals were deemed adequate for shareholders
Market Reality Check
Peers on Argus
Only one closely related peer, TNDM, appeared in the momentum scanner, moving up with no same-day peer news flow, suggesting INMD’s setup was more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 10 | Earnings results | Neutral | -3.3% | Reported Q4 and full-year 2025 results and 2026 outlook. |
| Feb 03 | Conference participation | Neutral | -4.3% | Announced participation in BTIG MedTech and investor meetings. |
| Feb 02 | Strategic review start | Positive | +5.8% | Confirmed evaluation of strategic alternatives after transaction rumors. |
| Jan 28 | Acquisition offer | Positive | -0.8% | Steel Partners presented $18.00 per share offer for 51% of INMD. |
| Jan 08 | Earnings date & guide | Neutral | -8.8% | Set Q4/FY 2025 report date and gave preliminary revenue guidance. |
News on strategic alternatives and transaction proposals has drawn mixed reactions, while several neutral or operational updates have coincided with share price declines.
Over the last few months, INMD has focused on financial reporting and strategic review. An $18.00 per share offer for 51% of the company and subsequent confirmation of strategic alternatives on 2026-02-02 framed expectations around potential transactions. Earnings-related updates on 2026-02-10 and earlier guidance and conference notices often coincided with negative price reactions. Today’s decision by the independent transaction committee to discontinue the transaction process follows this sequence of strategic and financial communications.
Market Pulse Summary
This announcement concludes an independent review of transaction proposals without pursuing a deal, after earlier disclosures about strategic alternatives and a partial acquisition proposal. Investors may focus on how INMD executes its stated business and cash allocation strategy to enhance long-term shareholder value. Recent filings highlighted substantial cash, ongoing share repurchases, and exposure to global medical device markets, alongside legal and geopolitical risks that remain important to monitor following the committee’s decision.
Key Terms
radio frequency ("rf") technical
otolaryngology medical
AI-generated analysis. Not financial advice.
YOKNEAM,
Since its formation, the Committee has conducted a comprehensive and independent process to evaluate proposals received over the course of its work, with the assistance of external financial and legal advisors.
Following a careful review of the final proposals received in connection with the potential transaction, the Committee has concluded that none of the final proposals is adequate and in the best interests of the Company and its shareholders. Accordingly, the Committee has determined to discontinue the process at this time.
The Company will continue to review and evaluate its business and growth strategy, as well as its cash allocation strategy, with a focus on enhancing long-term shareholder value.
The Company does not intend to provide further updates regarding this matter unless and until it determines that additional disclosure is appropriate or required.
About InMode
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radio frequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.
Forward-Looking Statements
The information in this press release includes forward-looking statements within the meaning of the federal securities laws. Actual outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. In some cases, you can identify these statements because they contain words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," "would" and similar expressions that concern our expectations, strategic plans or intentions. Forward-looking statements are based on management's current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Consequently, actual results could differ materially from those indicated in these forward-looking statements. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements included in InMode's Annual Report on Form 20-F filed with the Securities and Exchange Commission on February 10, 2026, and our future public filings. InMode undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which pertain only as of the date of this press release.
Logo - https://mma.prnewswire.com/media/1064477/InMode_Logo.jpg
Contacts
Miri Segal
MS-IR LLC
ir@inmodemd.com
View original content:https://www.prnewswire.com/news-releases/inmode-announces-conclusion-of-independent-transaction-committee-review-302694503.html
SOURCE InMode Ltd.
FAQ
Why did InMode (INMD) end its transaction committee process on Feb 23, 2026?
Will InMode (INMD) pursue a sale or merger after ending the review?
How should investors interpret InMode's (INMD) statement on no further updates?
What immediate impact does the discontinuation have on InMode's (INMD) strategic plan?
Did InMode (INMD) use external advisors during the transaction review?
